Cagrilintide

Metabolic & weight Investigational (in clinical trials)

Long-acting amylin analogue · also known as NNC0174-0833

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Amylin is a pancreatic hormone released with insulin that promotes fullness. Cagrilintide is a lipidated analogue built for weekly dosing. It has been tested alone in a dose-finding phase 2 trial and is best known as the amylin half of the CagriSema combination with semaglutide, which has been under regulatory review. Cagrilintide on its own is not approved.

Commonly reported dosing (5 mg vial)

Reconstituted with 1 mL → 5 mg/mL.

Also sold in 10 mg vials.

Phase	Dose	Volume	U-100 units
Starting	600 mcg	0.12 mL	12
Standard	2.4 mg	0.48 mL	48
Higher Top arm of the phase 2 dose-finding trial.	4.5 mg	0.9 mL	90

Frequency: Once weekly, subcutaneous · Half-life: Long-acting; supports once-weekly dosing

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-2	600 mcg	0.12 mL	12
Weeks 3-4	1.2 mg	0.24 mL	24
Weeks 5-6	2.4 mg	0.48 mL	48
Week 7+	4.5 mg	0.9 mL	90

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
1 mL of bacteriostatic water is added slowly down the inside wall of the 5 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (around -20 °C) and protected from light. Moisture is commonly avoided.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

How it works

It activates amylin and calcitonin-family receptors, with central effects on satiety and slowed gastric emptying, which together reduce food intake.

Researched for

Dose-finding phase 2 trial in adults with overweight or obesity (0.3 to 4.5 mg weekly over 26 weeks), with dose-dependent weight loss and mainly gastrointestinal side effects.
Combination studies with semaglutide as CagriSema.

Notes

The four-step ladder in the titration field, moving every two weeks, matches the escalation of the 4.5 mg arm in the phase 2 trial; it is one trial arm, not a general schedule.
A 5 mg vial reconstituted to 1 mL gives 5 mg/mL; a 10 mg vial reconstituted to 3 mL gives about 3.3 mg/mL, so the 4.5 mg step needs 1.35 mL and exceeds a 1 mL syringe.
Nausea and other gastrointestinal effects were the most common adverse events in trials.